Skip to Content

Rule

New Animal Drugs; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for an approved abbreviated new animal drug application (ANADA) from Inhalon Pharmaceuticals, Inc., to Minrad, Inc.

DATES:

This rule is effective April 2, 2001.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Norman J. Turner, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0214.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Inhalon Pharmaceuticals, Inc., P.O. Box 21170, Lehigh Valley, PA 18002, has informed FDA that it has transferred to Minrad, Inc., 836 Main St., 2d floor, Buffalo, NY 14202, ownership of, and all rights and interests in, ANADA 200-141 for Isoflurane, USP. Accordingly, the Start Printed Page 17510agency is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) and § 529.1186 (21 CFR 529.1186) to reflect the transfer of ownership.

In addition, Minrad, Inc., has not been previously listed in the animal drug regulations as a sponsor of an approved application. At this time, § 510.600(c) is being amended to add entries for the firm. Since Inhalon Pharmaceuticals, Inc., no longer is the sponsor of any approved new animal drug application, their drug labeler code (060307) is being reassigned to Minrad, Inc., as requested. This drug labeler code was removed from § 529.1186(b) in error (60 FR 40455, August 9, 1995), and it is being added at this time.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 510—NEW ANIMAL DRUGS

End Part Start Amendment Part

1. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

End Authority Start Amendment Part

2. Section 510.600 is amended in the table in paragraph (c)(1) by removing the entry for “Inhalon Pharmaceuticals, Inc.,” and by alphabetically adding an entry for “Minrad, Inc.,” and in the table in paragraph (c)(2) by revising the entry for “060307” to read as follows:

End Amendment Part
Names, addresses, and drug labeler codes of sponsors of approved applications.
* * * * *

(c)  *  *  *

(1)  *  *  *

Firm name and addressDrug labeler code
*         *         *         *         *         *         *
Minrad, Inc., 836 Main St., 2d floor, Buffalo, NY 14202060307
*         *         *         *         *         *         *

(2)  *  *  *

Drug labeler codeFirm name and address
*         *         *         *         *         *         *
060307Minrad, Inc., 836 Main St., 2d floor, Buffalo, NY 14202
*         *         *         *         *         *         *
Start Part

PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS

End Part Start Amendment Part

3. The authority citation for

End Amendment Part Start Authority

Authority: 21 U.S.C. 360b.

End Authority
[Amended]
Start Amendment Part

4. Section 529.1186

End Amendment Part Start Signature

Dated: March 2, 2001.

Claire M. Lathers,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 01-8059 Filed 3-30-01; 8:45 am]

BILLING CODE 4160-01-S